Bayer

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer growth in men with metastatic hormone-sensitive prostate cancer. About 223 men will receive darolutamide plus ADT, and their results will be compared to men from an earlier study who r…

This study offers ongoing treatment with darolutamide to cancer patients who were already taking it in a previous Bayer-sponsored study and whose doctors believe they are still benefiting. About 402 participants will continue their same dose and attend regular check-ups. The main…

This study looks at how safe and effective the drug darolutamide is for men with prostate cancer that has not spread to other parts of the body and is no longer responding to hormone therapy. About 805 men are being observed in real-world clinics, where their doctors already chos…

This study tested the safety and correct dose of the drug riociguat in 24 children aged 6 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard for the heart to pump blood. The children took different doses over several weeks, and researche…

This study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers want to see how many men reach very low PSA levels after one year and how the treatment affects their d…

This study follows over 1,000 Japanese patients with renal anemia (low red blood cells due to kidney disease) who are taking Molidustat. Researchers are monitoring safety issues like blood clots, high blood pressure, and heart problems, as well as whether the drug boosts red bloo…

This observational study tracks 33 adults with hemophilia A who choose to take Jivi, a longer-lasting clotting factor. Researchers use ultrasound to see if joint health improves or stays stable after 24 months of treatment. The goal is to understand how well Jivi works in everyda…

This study tests an experimental drug, BAY 2927088, in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The drug aims to block these abnormal proteins to stop cancer growth. The trial will first find the safest dose and then che…

This study is for people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study and are benefiting from it. They can continue taking the same dose to see how safe and tolerable it is over a longer period. The study involves about 13 participan…

This study looks at the safety and effectiveness of the drug sorafenib (Nexavar) in people with a type of advanced thyroid cancer that cannot be removed by surgery. Over 450 participants are being followed for up to 2 years to track side effects, how long they stay on the drug, a…

This study follows children with congenital heart disease who have had the Fontan procedure and are prescribed rivaroxaban, a blood thinner, to prevent dangerous clots. Researchers will track bleeding events and other side effects using data from regular doctor visits. The goal i…

This early-stage study tests a gene therapy called BAY2599023 in 11 adults with severe hemophilia A. The treatment delivers a healthy copy of the factor VIII gene so the body can produce its own clotting protein. The goal is to find a safe dose that raises clotting factor levels …

This early-phase study tests a new drug, BAY 3375968, that targets a protein on immune-suppressing cells to help the body fight advanced solid tumors. About 129 adults with cancers like lung, breast, head and neck, stomach, or melanoma will receive the drug alone or with pembroli…

This study tests whether adding darolutamide to standard hormone therapy (ADT) can delay cancer spread or death in men with high-risk biochemical recurrence of prostate cancer. About 985 men will receive either darolutamide plus ADT or a placebo plus ADT for up to 24 months. The …

This early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing nearby he…

This study tests a new drug called aficamten in 36 Japanese adults with a heart condition that makes the heart muscle too thick, making it hard to pump blood. The drug works by relaxing the heart muscle to improve blood flow. Researchers will check if it reduces symptoms and impr…

This study compares two treatments for men with prostate cancer that has spread to bones and is no longer responding to hormone therapy. One group receives radium-223, a radioactive drug that targets bone tumors, while the other continues with standard oral hormone drugs. The goa…

This study collects information from medical records of 700 Canadian men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how doctors combine treatments like hormone therapy, newer drugs, and chemotherapy. No new treatments are given—researchers simply observe wha…

This study observes over 4,600 adults with chronic kidney disease and type 2 diabetes who are already taking finerenone as part of their routine care. Researchers will collect data from medical records and doctor visits for 12 months to see how the drug is used, why it might be s…

This study watches adults with a type of liver cancer that can't be removed by surgery. They have already received a first-line treatment and are now starting a second treatment. Researchers will collect data from medical records to see how long patients live and how well the sec…

This study watches how Jivi (damoctocog alfa pegol) is used in routine care for people with hemophilia A. It tracks how many bleeds occur, any side effects, and how satisfied patients and doctors are with the treatment. About 371 people who have used Jivi before are taking part, …

This study follows 62 people with hemophilia A who are already using Jivi (damoctocog alfa pegol) to prevent bleeding. Researchers will collect safety data during routine doctor visits for at least 4 years. The goal is to better understand long-term side effects of this extended …

This study reviews medical records of 1200 Indian adults with chronic kidney disease and type 2 diabetes who started finerenone between 2022 and 2024. Researchers will describe how doctors prescribed the drug, dose changes, and effects on kidney function and potassium levels. The…

This study looks back at medical records of over 600 Indian adults with chronic heart failure who were prescribed vericiguat between 2022 and 2023. Researchers want to see how the drug is used in routine care, how it affects heart function and hospital stays, and whether side eff…

This study looks at health records from 150,000 people with chronic kidney disease and type 2 diabetes to see how safe and effective the drug finerenone is in everyday medical care. Researchers will compare those who take finerenone with those who do not, focusing on heart attack…

This study looks at how aflibercept 8 mg, a drug injected into the eye, is used in routine care for people with age-related macular degeneration or diabetic macular edema in Japan. Researchers will analyze existing health records from about 3000 patients to understand who gets th…

This study watches Japanese babies with retinopathy of prematurity (ROP) who are already getting Eylea eye injections. Researchers will track side effects and check if the treatment stops active ROP for up to 6 months. No extra tests are done—just routine care data is collected.…

This study observes Japanese men with metastatic hormone-sensitive prostate cancer who are already receiving darolutamide plus standard hormone therapy and chemotherapy. Researchers will collect data from regular doctor visits to monitor heart-related side effects and other safet…

This study looks at medical records from Finland and Sweden to count how many women with multiple sclerosis (MS) used the drug interferon-beta during the later stages of pregnancy (second and third trimesters). The goal is to see if there are enough cases to study whether the med…

This study watches how well aflibercept 8 mg works in real life for people with vision loss from age-related macular degeneration or diabetic eye swelling. Researchers will track vision changes over 12 months using routine doctor visits. No extra tests or visits are required—just…

This study was designed to see how a new experimental drug for chronic kidney disease, called nurandociguat, affects the way the body processes two common medicines (rosuvastatin and dabigatran) in healthy adults. The goal was to gather safety and drug-interaction information for…